Key result
Review outlines mechanisms of endothelium-derived constricting factor with a focus on endothelin.
Why the study?
Relatively little is known about endothelium-derived constricting factors (EDCF), especially the newly discovered vasoconstrictor peptide endothelin (ET).
This review summarizes early data on endothelium-derived constricting factors, particularly the newly discovered vasoconstrictor endothelin.
Endothelin may mediate vasoconstriction; extends early EDCF observations but leaves open clinical relevance pending trials.
The vascular endothelium is not merely a passive physical barrier between the blood and the tissue surrounding the blood vessel, but may actively participate in key processes of metabolic, secretory, and vasoregulatory character. In addition, the endothelium plays an important role in the control of platelet activation. Under certain conditions endothelial cells have been shown to produce powerful vasodilators, like endothelium-derived relaxing factor (EDRF) and prostacyclin (GPI2), and vasoconstrictors like endothelium-derived constricting factor (EDCF) and endothelin (ET) (Griffith et al., 1988; Vanhoutte & Katusic, 1988). In contrast to the extensive studies performed to characterize the actions and nature of EDRF, recently identified chemically as nitric oxide (Moncada et al., 1988), relatively little is known about EDCF(s). This paper reviews recent data on EDCF, with special emphasis on the newly discovered vasoconstrictor peptide, endothelin (ET).
No takes yet. Share an insight, caveat, or question.
Karwatowska‐Prokopczuk et al. (1990) reported a review. Endothelin (ET) and endothelium-derived constricting factor (EDCF) was evaluated. This review summarizes recent data on endothelium-derived constricting factor (EDCF), with a special emphasis on the newly discovered vasoconstrictor peptide, endothelin (ET).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: